ArticleScientific reports2026
CD47 as a prognostic biomarker and potential immunotherapy target in penile squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Penile squamous cell carcinoma (PSCC) remains a global healthcare concern, characterized by poor outcomes and limited therapeutic options. CD47, a “don’t-eat-me” signal that enables tumor immune evasion, has not been extensively evaluated in PSCC. This study aims to explore the expression and significance of CD47 in PSCC. RNA-sequencing was performed on eight paired PSCC and adjacent normal tissues. Protein expression was assessed by immunohistochemistry (IHC) in an independent of 131 PSCC cases, and associations with clinicopathological factors and prognosis was evaluated. In addition, the interrogation of CD47-interacting proteins, immune cell infiltration, and signaling pathways related to CD47 subgroups were analyzed from the public database. CD47 mRNA levels were higher in PSCC tumors compared to normal tissues. High CD47 protein expression (41.98%, 55/131) significantly correlated with advanced tumor stage (P = 0.002) and larger tumor size (P = 0.002). With a median follow-up of 38 months, Kaplan-Meier survival analysis demonstrated that patients with high CD47 expression had significantly poorer overall survival (OS) (P = 0.006). Multivariate Cox regression analysis confirmed that high CD47 expression remained an independent predictor of poor OS (HR = 9.956, 95% CI 2.410–41.141, P = 0.001). Functional enrichment analyses of CD47-interacting proteins indicated involvement in immune-related and adhesion-associated pathways. Furthermore, immune infiltration analyses using CIBERSORT and IHC revealed that high CD47 expression was associated with reduced CD8 + T-cell infiltration. Gene set variation and enrichment analyses suggested activation of MYC targets and mTORC1 signaling in the high-CD47 group, which was further validated by increased phosphorylated S6K1 expression observed through IHC. These findings provide novel evidence that CD47 may serve as a promising prognostic biomarker and a potential immunotherapeutic target for PSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.